Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PDE5 inhibitor exposure and risk of NAION in men: prospective case-crossover study
2010-023586-22Phase 4Completed
- Sponsor
- Bayer
- Start
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of vardenafil, sildenafil, tadalafil and avanafil in non-arteritic anterior ischemic optic neuropathy (NAION), sponsored by Bayer. Primary endpoint: Relative risk of NAION associated with PDE5 inhibitor exposure. Started Dec 2011; status: completed.
02
Drugs
vardenafilsildenafiltadalafilavanafil
03
Conditions
non-arteritic anterior ischemic optic neuropathy (NAION)
Beyond the preview
Go deeper on 2010-023586-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023586-22.